Tianeptine

Tianeptine is a racemate comprising of equimolar amounts of (R)- and (S)-tianeptine. It is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs). Among its listed roles, it functions as a anxiolytic drug, a mu-opioid receptor agonist and a second generation antipsychotic. It includes a (S)-tianeptine and a (R)-tianeptine. Tianeptine is a drug used mainly in the treatment of major depressive disorder and has been studied in the treatment of irritable bowel syndrome (IBS). Structurally, it is classified as a tricyclic antidepressant (TCA), however, it possesses different pharmacological properties than typical tricyclic antidepressants. Tianeptine was discovered and patented by The French Society of Medical Research in the 1960s. Currently, tianeptine is approved in France and manufactured and marketed by Laboratories Servier SA; it is also marketed in several other European countries under the trade name “Coaxil” as well as in Asia (including Singapore) and Latin America as “Stablon” and “Tatinol” but it is not available in Australia, Canada, New Zealand, the U.K. or the U.S. It is grouped under the following drug class(es): Psychotropic agents. Its therapeutic use is listed as antidepressants. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Stablon and Tianeptina. Its PubChem CID is 68870.

CAS No 72797-41-2
Molecular Formula C21H25ClN2O4S
Molecular Weight 437.0 g/mol
Synonyms 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid

Frequently Asked Questions